Targeting SNCA/TFRC and Overcoming the BBB: The Future of Parkinson’s Disease Therapeutics

PD Pathophysiology and alpha-Synuclein Aggregation

PD is primarily characterized by the progressive loss of dopaminergic neurons in the brain, resulting in symptoms such as tremors, rigidity, and motor impairments. According to statistics from the Parkinson’s Foundation (PF), more than 10 million people worldwide are living with PD, and its prevalence is projected to double over the next 30 years ^[5]. PD exhibits significant heterogeneity in its clinical presentation, pathological features, and genetic profiles, often categorized into rapid-progressing and slow-progressing types. Regardless of the progression rate, there is currently no cure; patients are limited to symptomatic treatments aimed at alleviating both motor and non-motor symptoms ^[6].

The risk factors for PD include age, sex, pesticide exposure, traumatic brain injury, and family history. The pathology of PD is primarily defined by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the accumulation of misfolded alpha-synuclein protein in the form of Lewy bodies (LBs) ^[7].

Figure 2. Projected age standardised prevalence (per 100 000) of PD in 2050, by country and territory for both sexes combined ^[8].

Targeting SNCA Mutations via RNAi and Gene Therapies

Research over the last two decades has identified more than 100 distinct genes that are clearly linked to a person’s risk of developing PD ^[9]. Despite this high number of discoveries, SNCA remains the most significant, as it was the very first gene ever identified in connection with the condition.It encodes the alpha-synuclein protein and is considered one of the primary genes responsible for the disease. Mutations in the SNCA gene can cause an overproduction of alpha-synuclein (α-syn), which leads to the formation of Lewy bodies. These deposits are found throughout the central and peripheral nervous systems of Parkinson's patients and eventually lead to the onset of the disease ^[10-11]. Because of this, both the SNCA gene and the alpha-synuclein protein are seen as effective targets for treatment.

Since alpha-synuclein is an intrinsically disordered protein that lacks a typical binding site, it is very difficult to treat with traditional small-molecule drugs. New treatment strategies focus on reducing the overproduction of the protein, breaking it down, or preventing it from clumping together to stop Lewy bodies from forming. These approaches include gene therapies that target the SNCA gene or its mRNA, RNAi drugs like ASOs and siRNAs, and antibody-based treatments that target the protein itself ^[12-15]. No matter which method is used, it must precisely target human genes or proteins. Therefore, it is essential to have preclinical research models that express the human SNCA gene when developing these drugs. The creation and use of these models will certainly open up new possibilities for PD research and treatment.

Figure 3. Antisense oligonucleotides (ASOs) reduce production of α-Syn in mouse models of PD ^[16].

Validating CNS Efficacy Using Humanized and In Vitro Models

To address the urgent need for innovative Parkinson’s Disease (PD) therapies, Cyagen offers a comprehensive preclinical research platform encompassing rigorously validated in vitro cellular systems, diverse induced models, and advanced genetically engineered models. Within our genetic portfolio, we are particularly specialized in supporting the development of SNCA-targeted gene therapies and RNAi drugs. Central to our offerings is the Humanized SNCA (with 3'UTR) model (Product ID: C001698), which provides a comprehensive genetic environment for testing therapies that regulate gene expression. For innovative programs targeting the blood-brain barrier (BBB)—such as ARO-SNCA and other therapies utilizing TfR1-mediated transport—we also offer a specialized huTFRC/huSNCA(3'UTR) dual-humanized model (Product ID: C001873) to evaluate CNS delivery and efficacy in a single system. Complementing these advanced genetic tools, we also offer a robust selection of AAV- and neurotoxin-induced in vivo models, alongside disease-relevant cellular platforms, providing a complete translational pipeline for diverse mechanism-of-action (MOA) studies.

Recapitulating PD Phenotypes via Systemic AAV-A53T Induction

As a highlight of our evolving disease model portfolio, we are proud to introduce our newly validated AAV-Induced PD Mouse Model (AAV9.CNS-Mut-CAG-hαSyn-A53T). Unlike traditional stereotaxic injection models, this innovative model utilizes a single intravenous (IV) injection of a BBB-penetrating AAV vector to systemically deliver human A53T-mutant alpha-synuclein. Detailed longitudinal validation demonstrates robust phenotypic recapitulation:

Behavioral validation：

Figure 4. Mice exhibit significant motor coordination and gait impairments (assessed via Rotarod and high-speed Gait analysis) as early as 1.5 months post-injection, closely mimicking PD-like motor symptoms.

Pathological Validation

Figure 5. Whole-Brain Expression of Human α-Synuclein Across Mouse Groups at 3.5–4 Months Post-Injection. Upon detection, humanα-synuclein can be detected across the brain in G1, but not in G2, indicating extensive AAV-mediated protein expression.

Figure 6. Localization of Human α-Synuclein in the Mouse Cortex and Striatum at 3.5–4 Months Post-Injection.

Figure 7. Whole-Brain Phosphorylated α-Synuclein Expression at 3.5–4 Months Post-Injection.

In addition to our proprietary AAV models, Cyagen provides a comprehensive suite of classic neurotoxin and functionally-induced PD models to support diverse mechanism-of-action (MOA) studies:

• WT or hSNCA (3'UTR) + PFF
• 6-OHDA induced model
• Acute MPTP-induced model
• Subacute MPTP-induced model

In Vitro Solutions: Disease-Relevant Cell Lines for PD Research

Cyagen offers a diverse array of rigorously validated cell lines optimized for neurodegenerative disease research. These cellular models provide researchers with robust, scalable in vitro systems for high-throughput screening, mechanistic studies, and preliminary neurotoxicity assessments prior to transitioning to animal models.

Conclusion

Parkinson’s disease research is moving away from just managing symptoms and toward addressing the genetic causes of the disease. As the number of patients worldwide continues to grow, the SNCA gene has become the primary focus for developing new treatments that can actually change the course of the disorder. However, the real breakthrough depends on more than just gene targeting—it requires a reliable way to get these treatments past the blood-brain barrier without invasive surgery.

New delivery methods, such as TfR1-mediated transport and platforms like TRiM™ BBB, are finally making it possible to deliver powerful RNAi and gene therapies through a simple injection. To turn these scientific advances into successful clinical results, researchers need high-fidelity testing tools. Cyagen provides this essential foundation through specialized products like the Humanized SNCA (with 3'UTR) model and the huTFRC/huSNCA dual-humanized model, which are designed specifically to evaluate CNS delivery and efficacy. By combining these precise genetic models with Cyagen’s expert neuroscience CRO services—including stereotactic injections and detailed neurobehavioral analysis—we are no longer just tracking the decline of Parkinson’s patients; we are building the tools to stop the disease at its source.

References